|
WO2020193419A1
|
|
Novel potassium channel inhibitors
|
|
WO2020144146A1
|
|
Tesofensine for reduction of body weight in prader-willi patients
|
|
WO2020084065A1
|
|
Transdermal tropane compositions and methods for using the same
|
|
CA3058933A1
|
|
Tesofensine for reduction of body weight in prader-willi patients
|
|
CA3110283A1
|
|
A gaba a receptor ligand
|
|
CA3029052A1
|
|
Tesofensine for reduction of body weight in prader-willi patients
|
|
US2018311238A1
|
|
Selective Agonist Of a6 Containing nAChRs
|
|
WO2018046599A1
|
|
Tesofensine compositions
|
|
CN109475535A
|
|
The combination therapy of cancer
|
|
WO2017121432A1
|
|
Tesofensine and metoprolol for treatment of hypertension
|
|
AU2016228002A1
|
|
Tesofensine, beta blocker combination formulation
|
|
US2015203458A1
|
|
Tetrazole derivatives and their use as potassium channel modulators
|
|
HUE043019T2
|
|
Pharmaceutical compositions for combination therapy
|
|
EP2814473A1
|
|
Pharmaceutical compositions for combination therapy
|
